Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study

References

• Global Initiative for Asthma (GINA). Available from: http://www.ginasthma.org. [last accessed 10 Jan 2023].
   Google Scholar
• Campo P, Soto Campos G, Aparicio MB, Jorge AM, González Expósito HM, Dávila I. Severe asthma phenotypes in patients controlled with omalizumab: a real-world study. Respir Med 2019;159:105804.
   PubMed Web of Science ®Google Scholar
• Tabatabaian F, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy 2018;11:53–61.
   PubMed Web of Science ®Google Scholar
• Kopp MV. Omalizumab: anti-IgE therapy in allergy. Curr Allergy Asthma Rep 2011;11:101–106.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, Moss R, Denning DW. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013;43:850–873.
   PubMed Web of Science ®Google Scholar
• Asthma Control Test. Welcome to the Asthma Control Test. Available from: https://www.asthmacontroltest.com/tr-tr/quiz/adult-quiz/. [last accessed 12 Nov 2022].
   Google Scholar
• Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–338.
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, Durham S, et al. The skin prick test – European standards. Clin Transl Allergy 2013;3:3.
   PubMedGoogle Scholar
• Arslan B, Paçacı Çetin G, Türk M, Gülmez İ, Yılmaz İ. Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level be used as a biological marker to decide discontinuing omalizumab treatment? Int Arch Allergy Immunol 2022;183:1071–1077.
   PubMed Web of Science ®Google Scholar
• Miralles-López JC, Andújar-Espinosa R, Bravo-Gutiérrez FJ, Castilla-Martínez M, Flores-Martín I, Alemany-Francés ML, Pajarón-Fernández MJ, et al. Analysis of response of severe eosinophilic asthmatic patients to benralizumab. Allergol Immunopathol 2022;50:163–168.
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Zhang B, Yu Q, Lu Y. Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis. Expert Rev Respir Med 2022;16:1023–1033.
   PubMed Web of Science ®Google Scholar
• Fomina DS, Mukhina OA, Lebedkina MS, Gadzhieva MK, Bobrikova EN, Sinyavkin DO, Parshin VV, et al. Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice. Ter Arkh 2022;94:413–419.
   PubMed Web of Science ®Google Scholar
• Kallieri M, Papaioannou AI, Papathanasiou E, Ntontsi P, Papiris S, Loukides S. Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgrad Med 2017;129:598–604.
   PubMed Web of Science ®Google Scholar
• Akaba T, Kondo M, Kobayashi F, Honda N, Muramatsu S, Yagi O, Takeyama K, Seo Y, Nonaka M, Tagaya E. Characteristics of patients with severe asthma who experienced treatment failure with omalizumab. Pulm Pharmacol Ther 2021;68:102032.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020;146:595–605.
   PubMed Web of Science ®Google Scholar
• Damask C, Chen M, Holweg CTJ, Yoo B, Millette LA, Franzese C. Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis. Am J Rhinol Allergy 2022;36:135–141.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE, Ow RA, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol 2022;149:957–965.
   PubMed Web of Science ®Google Scholar
• Zheng M, Sima Y, Liu C, Zhao J, Shao S, Wang X, Wang Y, et al. Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers - a real-life prospective study. World Allergy Organ J 2022;15:100702.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy 2020;75:1023–1042.
   PubMed Web of Science ®Google Scholar
• Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy 2020;75:1043–1057.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract 2021;9:2702–2714.
   PubMed Web of Science ®Google Scholar
• Cavaliere C, Begvarfaj E, Incorvaia C, Sposato B, Brunori M, Ciofalo A, Greco A, et al. Long-term omalizumab efficacy in allergic rhinitis. Immunol Lett 2020;227:81–87.
   PubMed Web of Science ®Google Scholar
• Tsabouri S, Ntritsos G, Koskeridis F, Evangelou E, Olsson P, Kostikas K. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. Rhinology 2021;59:501–510.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xi L, Gao Y, Huang Y, Cao F, Xiong W, Wang C, Zhang L. Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis. Clin Transl Allergy 2022;12:e12094.
   PubMed Web of Science ®Google Scholar